Skip to content
Clear Signal
Tech and scienceReportOpen the first report

Experts expect the personalised melanoma vaccine to receive US approval in 2027 following positive late-stage trial results.

  • Intismeran autogene (V940)
  • KEYTRUDA
  • FDA
Head start9d
New Scientist, Carissa Wong
KalshiWill the FDA approve intismeran autogene (V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment of completely resected stage IIB-IV melanoma before Oct 1, 2027?59¢to90¢

Markets

PriceMoveHead startNow

Reports

  1. 0sFirstNew Scientist, Carissa Wong
  2. +1h 6mRepeatedNew Scientist
  3. +26h 49mRepeatedNew Scientist
  4. +9dRepeatedNew Scientist
  5. +9d59¢to90¢
UTC